Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.81 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5389014 | 0.89 | ALDH1A1 (1.00) | ALDH1A1RECQLHPGDCA1AKT1 | |
| SCHEMBL5389556 | 0.89 | ALDH1A1 (0.77) | ALDH1A1RECQLHPGDAKT1ATM | |
| SCHEMBL11891684 | 0.89 | ALDH1A1 (0.77) | ALDH1A1RECQLHPGDCA1CA2 | |
| Glysobuzole SCHEMBL1815623 | 0.87 | ALDH1A1 (1.00) | ALDH1A1RECQLHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL5391543 | 0.86 | ALDH1A1 (0.72) | ALDH1A1RECQLHPGDAKT1ATM | |
| SCHEMBL11893076 | 0.86 | AKT1 (0.77) | ALDH1A1RECQLHPGDCA1CA2 | |
| SCHEMBL11891683 | 0.84 | AKT1 (0.77) | ALDH1A1CA1CA2AKT1HSD17B10 | |
| SCHEMBL10555986 | 0.82 | RECQL (0.68) | ALDH1A1RECQLCA1CA2AKT1 | |
| SCHEMBL11891689 | 0.82 | AKT1 (0.79) | ALDH1A1AKT1 | |
| SCHEMBL5398574 | 0.80 | ALDH1A1 (0.73) | ALDH1A1RECQLHPGDCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173030-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | claimed |
| EP-1631558-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2006-03-08 | — | — | EP | claimed |
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2005-01-13 | — | — | US | claimed |
| WO-2004103980-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2004-12-02 | — | — | WO | claimed |
| US-4810397-A | ALUMINUM COMPOUND, ACID, THIADIAZOLE OR TRIAZOLE | UNION OIL COMPANY OF CALIFORNIA (US) | 1989-03-07 | — | — | US | claimed |
| US-4719001-A | ALUMINUM COMPOUND AND THIADIAZOLE DERIVATIVE | UNION OIL COMPANY OF CALIFORNIA (US) | 1988-01-12 | — | — | US | claimed |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2007-03-22 | — | — | US | disclosed |
| US-7173030-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| EP-1631558-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2005-01-13 | — | — | US | disclosed |
| WO-2004103980-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2004-12-02 | — | — | WO | disclosed |
| US-4810397-A | ALUMINUM COMPOUND, ACID, THIADIAZOLE OR TRIAZOLE | UNION OIL COMPANY OF CALIFORNIA (US) | 1989-03-07 | — | — | US | disclosed |
| US-4719001-A | ALUMINUM COMPOUND AND THIADIAZOLE DERIVATIVE | UNION OIL COMPANY OF CALIFORNIA (US) | 1988-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 53/4885RECQL 1071/4885HPGD 44/4885 |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | ALDH1A1 36/4885RECQL 1173/4885HPGD 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.